PATH01.03 Mutational Landscape and Prognosis Prediction for Immune Checkpoint Blockades of DNA Damage Response Pathways in Non-Small Cell Lung Cancer

L. Zhong,J. Zhao,X. Zhao,W. Xie,Y. Bai

DOI: https://doi.org/10.1016/j.jtho.2020.10.077

IF: 20.121

2021-01-01

Journal of Thoracic Oncology

Abstract:DNA damage response (DDR) pathways which play a key role in maintaining the genome stability, have been reported to be associated with higher tumor mutational burden (TMB) and improved clinical benefit of immune checkpoint blockades (ICBs) in non-small cell lung cancer (NSCLC). Our study aimed to reveal the mutation landscape of DDR pathways and their association with TMB and PD-L1 in a Chinese NSCLC cohort, and explore the potential prognosis prediction in patients treated with ICBs. A total of 3428 NSCLC patients who underwent next-generation sequencing (NGS) with a 381 genes panel in 3DMed Clinical Laboratory and 350 NSCLC patients treated with ICBs downloaded from Cbioportal were included in our analysis. Non-synonymous mutation of 30 DDR genes across six pathways were analyzed. Pathway mutation was defined as at least one gene mutation in the corresponding pathway. Ridge regression was used to analyze the association of DDR genes mutation and TMB levels. There are 2161 (63.0%) male and 1267 (37.0%) female patients, with a median age of 62 (IQR range, 54-68). DDR mutation was prevalent in 30.0% patients. The top five mutated DDR genes were ATM (168, 4.9%), BRCA2 (1311, 3.8%), ATR (112, 3.3%), POLE (100, 2.9%) and FANCA (69, 2.0%). The DDR pathway mutation frequency were 531 (15.5%) for fanconi anemia, 460 (13.4%) for homologous recombination, 334 (9.7%) for damage sensor, 206 (6.0%) for nucleotide excision repair, 182 (5.3%) for mismatch repair, 167 (4.9%) for base excision repair and 55 (1.6%) for non-homologous end joining. A total of 305 (8.9%) harbor at least two DDR genes mutation and 575 (16.8%) at least two DDR pathways mutation. In ridge regression, 18 DDR genes were significantly associated with TMB (FDR < 0.001). Among them, ATM, ATR, BRCA2, MLH1 and POLD1 had the highest coefficients. DDR mutation, TMB and PD-L1 expression on tumor cells were available for 2403 patients. In 730 patients with at least one DDR gene mutation, 184 (25.2%) patients were not in the group of TMB-high (top 20%) or positive PD-L1 (PD-L1 expression on tumor cells ≥1%). In 350 NSCLC patients treated with ICBs, DDR mutation (defined by DDR genes with FDR < 0.001 in ridge regression and mutation frequency > 1.5%) was significantly associated with prolonged overall survival (Hazard ratio = 0.70; 95% confidential interval = 0.51-0.97, P = 0.03). Our results indicated the wide prevalence of DDR pathways mutations in Chinese patients with NSCLC and validated the potential prognosis prediction of ICBs, which provide evidence for precise immune treatment in NSCLC.